Overview

A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes

Status:
Terminated

Trial end date:
2008-12-01

Target enrollment:

Participant gender:

Summary

A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes.

Phase:

Phase 1

Details

Lead Sponsor:

Celgene
Celgene Corporation